cancer weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of cancer weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Chronic Lymphocytic Leukemia
Novel DNA cross-linking agent has potent/selective cytotoxicity in CLL B cells
December 14th, 2004
A novel DNA cross-linking agent has potent and selective cytotoxicity in chronic lymphocytic leukemia B cells. "SJG-136 (NSC 694501) is a novel DNA cross-linking agent that binds in a sequence-selective manner in the minor groove of the DNA helix. It is structurally novel compared with other clinically used DNA cross-linking agents and has exhibited a unique multilog differential pattern of activity in the NCI 60-cell line screen (i.e, is COMPARE negative to other cross-linking agents). "Given this profile, we undertook a preclinical evaluation of SJG-136 in primary tumor cells derived from 34 B-cell chronic lymphocytic leukemia (B-CLL) patients,"...
Source: cancer weekly (2004-12-14)
|
